Amgen Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
Amgen Inc. (AMGN) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of -$20.00 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2015-11-02
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-09-30 was -$20.00M.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-06-30 was -$63.00M, a 625.00% decline year-over-year.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-03-31 was $83.00M, a 245.83% increase year-over-year.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2014-12-31 was $34.00M.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2014 was $14.00M.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2013 was -$133.00M, a 450.00% decline from fiscal 2012.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2012 was $38.00M.
- Amgen Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2011 was -$14.00M, a 156.00% decline from fiscal 2010.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$20.00M 10-Q · filed 2015-11-02 | -$83.00M derived: sum of 2 quarters · filed 2015-11-02 | $0.00 derived: sum of 3 quarters · filed 2015-11-02 | $34.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-06-30 | -$63.00M 10-Q · filed 2015-11-02 | $20.00M derived: sum of 2 quarters · filed 2015-11-02 | $54.00M derived: sum of 3 quarters · filed 2015-11-02 | -$2.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-03-31 | $83.00M 10-Q · filed 2015-11-02 | $117.00M derived: sum of 2 quarters · filed 2015-11-02 | $61.00M derived: sum of 3 quarters · filed 2015-11-02 | $73.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-12-31 | $34.00M derived: 10-K 12 month − 3 quarters · filed 2015-02-19 | -$22.00M derived: sum of 2 quarters · filed 2015-02-19 | -$10.00M derived: sum of 3 quarters · filed 2015-02-19 | $14.00M 10-K · filed 2015-02-19 |
| 2014-09-30 | -$56.00M 10-Q · filed 2014-10-29 | -$44.00M derived: sum of 2 quarters · filed 2014-10-29 | -$20.00M derived: sum of 3 quarters · filed 2014-10-29 | |
| 2014-06-30 | $12.00M 10-Q · filed 2014-10-29 | $36.00M derived: sum of 2 quarters · filed 2014-10-29 | ||
| 2014-03-31 | $24.00M 10-Q · filed 2014-10-29 | |||
| 2013-12-31 | -$133.00M 10-K · filed 2015-02-19 | |||
| 2013-09-30 | $28.00M 10-Q · filed 2013-10-29 | -$92.00M derived: sum of 2 quarters · filed 2013-10-29 | -$129.00M derived: sum of 3 quarters · filed 2013-10-29 | |
| 2013-06-30 | -$120.00M 10-Q · filed 2013-10-29 | -$157.00M derived: sum of 2 quarters · filed 2013-10-29 | ||
| 2013-03-31 | -$37.00M 10-Q · filed 2013-10-29 | |||
| 2012-12-31 | $38.00M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | -$14.00M 10-K · filed 2014-02-24 | |||
| 2010-12-31 | $25.00M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |